Dr Reddy’s Laboratories has launched paricalcitol capsules, 1 mcg, 2 mcg and 4 mcg, a therapeutic equivalent generic version of Zemplar (paricalcitol) capsules in the US market on June 24, 2014, following the approval by the US Food & Drug Administration (USFDA). Dr Reddy’s Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg are available in bottle counts of 30.
The Zemplar brand and generic had US sales of approximately $ 109.6 million MAT for the most recent twelve months ending in March 2014, according to IMS Health.
The Zemplar brand and generic had US sales of approximately $ 109.6 million MAT for the most recent twelve months ending in March 2014, according to IMS Health.